US media is busy with news of patients at a Chicago hospital who responded remarkably to experimental Remdesivir treatment, and discharged after less than a week, after the said drug relieved their fever and acute respiratory symptoms. Partial data showed encouraging signs after trials of a trial drug for an American company on Patients with severe cases of "Covid-19". According to "Reuters" and "Arab Net."
The (Stat) medical news website said that a University of Chicago hospital monitored a rapid recovery from symptoms of fever and respiratory system, with almost all patients leaving the hospital in less than a week.
He mentioned that the U Chicago Medicine Hospital recruited 113 volunteers with acute epidemics in order to take part in this experiment, adding that most of the participants left the hospital, while only two patients died.
An analysis of last week's New England Journal of Medicine showed that two-thirds of a small group of patients with severe cases of Covid-19 experienced an improvement in their condition after being treated with a remdivir drug.
The manufacturer of the drug confirmed that "the inclusion of data needs to be analyzed in order to extract any results from the experiment." The U Chicago Medicine Hospital said, "Partial data from an ongoing clinical trial are essentially incomplete and should not be used to draw conclusions."
Results from the third phase of the study are expected to be issued to patients with severe cases of Covid-19 at the end of the month, and additional data will be available from other studies in May.
It is noteworthy that until now there is no approved drug for Covid-19, which is a highly contagious disease caused by the emerging corona virus that has infected more than two million people worldwide.